government approval of antisense therapies for neuromuscular disease

Representatives from government, industry, research and patient groups met in Washington, D.C., Sept. 27-28 to discuss antisense-based therapies for neuromuscular disease

posted on October 1, 2010 - 2:24pm
This story was updated Oct. 6, 2010. Researchers, clinicians, pharmaceutical industry executives, and representatives from advocacy groups, including MDA, met in Washington Sept. 27-28, 2010, to discuss moving forward with antisense-based therapies for neuromuscular disease.

New content is being added every day. Please check back again.